PROBIOTICS FOR IRRITABLE BOWEL SYNDROME : A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i2.1535Keywords:
Bacteria, Irritable Bowel Syndrome, Probiotics, SynbioticAbstract
It has been demonstrated that dysbiosis, also known as imbalances or aberrations of microbiota, plays a significant role in FGIDs and allergens, including infection and antibiotic-associated diarrhea, food allergy, atopic eczema, inflammatory bowel syndrome, and irritable bowel syndrome. It has been demonstrated via research that the mechanisms of action of probiotics in irritable bowel syndrome are diverse, heterogeneous, and strain specific. For the purpose of understanding irritable bowel syndrome (IBS), the mechanism of action of probiotics has to be translated into a language that is more comprehensible from a clinical and a practical standpoint. The competitive exclusion mechanism of pathogens by luminal pH, competition for nutritional sources, and production of bacteriocins, SCFAs, and biosurfactants are all involved in the modulation of the gut microbiota. These factors all work together to prevent the proliferation of pathogens and inhibit their adhesion to the gut epithelia. Because the use of synbiotics as an alternative treatment for IBS is still in its infancy, and because the outcomes of synbiotic administration may be dependent on the probiotic component of the synbiotic, greater emphasis should be placed on determining patients' probiotic responses before beginning treatment with synbiotics.
References
Kerian K. Communication breakdown between physicians and IBS sufferers: what is the conundrum and how to overcome it? J r Coll Physicians edinb. 2017;47:138–41.
Sperber AD, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut. 2017;66(6):1075–82.
Lacy BE. Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2018 Oct;48(8):817–30.
Choi CH, Kwon JG, Kim SK, Myung S, Park KS, Sohn C, et al. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double?blind, placebo?controlled, multicenter, phase II trial. Neurogastroenterol Motil. 2015;27(5):705–16.
Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and synbiotics—approaching a definition. Am J Clin Nutr. 2001;73(2):361s-364s.
Barbara G, Cremon C, Azpiroz F. Probiotics in irritable bowel syndrome: Where are we? Neurogastroenterol Motil. 2018;30(12):e13513.
Labus JS, Hollister EB, Jacobs J, Kirbach K, Oezguen N, Gupta A, et al. Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome. Microbiome. 2017;5:1–17.
Lazaridis N, Germanidis G. Current insights into the innate immune system dysfunction in irritable bowel syndrome. Ann Gastroenterol. 2018;31(2):171.
Rao SSC, Go JT. Update on the management of constipation in the elderly: new treatment options. Clin Interv Aging. 2010 Aug;5:163–71.
Camilleri M. Management Options for Irritable Bowel Syndrome. Mayo Clin Proc. 2018 Dec;93(12):1858–72.
Staudacher HM, Scholz M, Lomer MC, Ralph FS, Irving PM, Lindsay JO, et al. Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probiotics. Clin Nutr. 2021 Apr;40(4):1861–70.
Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, et al. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology. 2017 Aug;153(2):448-459.e8.
Xu H, Ma C, Zhao F, Chen P, Liu Y, Sun Z, et al. Adjunctive treatment with probiotics partially alleviates symptoms and reduces inflammation in patients with irritable bowel syndrome. Eur J Nutr. 2021 Aug;60(5):2553–65.
Oh JH, Jang YS, Kang D, Chang DK, Min YW. Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2019 Nov;11(12).
Ankersen DV, Weimers P, Bennedsen M, Haaber AB, Fjordside EL, Beber ME, et al. Long-Term Effects of a Web-Based Low-FODMAP Diet Versus Probiotic Treatment for Irritable Bowel Syndrome, Including Shotgun Analyses of Microbiota: Randomized, Double-Crossover Clinical Trial. J Med Internet Res. 2021 Dec;23(12):e30291.
Lewis ED, Antony JM, Crowley DC, Piano A, Bhardwaj R, Tompkins TA, et al. Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled Study. Nutrients. 2020 Apr;12(4).
Skrzyd?o-Radoma?ska B, Prozorow-Król B, Cicho?-Lach H, Majsiak E, Bier?a JB, Kanarek E, et al. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study. Nutrients. 2021 Feb;13(3).
Radovanovic-Dinic B, Tesic-Rajkovic S, Grgov S, Petrovic G, Zivkovic V. Irritable bowel syndrome - from etiopathogenesis to therapy. Biomed Pap Med Fac Univ Palacky, Olomouc, Czechoslov. 2018 Mar;162(1):1–9.
Chlebicz-Wójcik A, ?li?ewska K. Probiotics, Prebiotics, and Synbiotics in the Irritable Bowel Syndrome Treatment: A Review. Biomolecules. 2021 Aug;11(8).
Doron S, Gorbach SL. Probiotics: their role in the treatment and prevention of disease. Expert Rev Anti Infect Ther. 2006;4(2):261–75.
Collado MC, Grze?kowiak ?, Salminen S. Probiotic strains and their combination inhibit in vitro adhesion of pathogens to pig intestinal mucosa. Curr Microbiol. 2007 Sep;55(3):260–5.
Martoni CJ, Srivastava S, Leyer GJ. Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: randomized controlled trial. Nutrients. 2020;12(2):363.
Auclair J, Frappier M, Millette M. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): characterization, manufacture, mechanisms of action, and quality control of a specific probiotic combination for primary prevention of Clostridium difficile infection. Clin Infect Dis. 2015;60(suppl_2):S135–43.
Meyer C, Vassar M. The fragility of probiotic Bifidobacterium longum NCC3001 use for depression in patients with irritable bowel syndrome. Gastroenterology. 2018;154(3):764.
Satish Kumar L, Pugalenthi LS, Ahmad M, Reddy S, Barkhane Z, Elmadi J. Probiotics in Irritable Bowel Syndrome: A Review of Their Therapeutic Role. Cureus. 2022 Apr;14(4):e24240.
Gorospe EC, Oxentenko AS. Nutritional consequences of chronic diarrhoea. Best Pract Res Clin Gastroenterol [Internet]. 2012;26(5):663–75. Available from: https://www.sciencedirect.com/science/article/pii/S1521691812001023
Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta?analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044–60.
Dale HF, Rasmussen SH, Asiller ÖÖ, Lied GA. Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review. Nutrients. 2019 Sep;11(9).
Jia Y, Guo L-M, Yang S-Y, Wu Q, Meng F-J. Effectiveness of probiotics in irritable bowel syndrome: methodological quality of meta-analyses and systematic reviews. Front Nurs. 2019;6(2):115–21.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Journal of Advance Research in Medical & Health Science
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
